CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease

Autor: Andreas Stang, Jan Rekowski, Markus Otto, Kathy Keyvani, Karl-Heinz Jöckel, Herrmann Esselmann, Hayrettin Tumani, Jonathan Vogelgsang, Sarah Teuber-Hanselmann, Christine A. F. von Arnim, Arne Herring, Kathrin Reetz, Jens Wiltfang
Rok vydání: 2019
Předmět:
Male
Oncology
Parkinson's disease
affective disorders
Medizin
Neuropsychological Tests
0302 clinical medicine
Blood serum
Cerebrospinal fluid
Kallikrein-8
0303 health sciences
Area under the curve
Human brain
Middle Aged
Prognosis
3. Good health
Psychiatry and Mental health
medicine.anatomical_structure
Disease Progression
biomarker
Biomarker (medicine)
Female
Kallikreins
Alzheimer’s disease
medicine.medical_specialty
KLK8
psychiatric disease
tau Proteins
cerebrospinal fluid
03 medical and health sciences
mild cognitive impairment
blood
Alzheimer Disease
Internal medicine
medicine
Humans
Dementia
Cognitive Dysfunction
ddc:610
Neurodegeneration
neuropsin
Aged
030304 developmental biology
Amyloid beta-Peptides
Receiver operating characteristic
business.industry
Reproducibility of Results
medicine.disease
Cross-Sectional Studies
Parkinson’s disease
Surgery
Neurology (clinical)
business
Biomarkers
030217 neurology & neurosurgery
Zdroj: Journal of neurology, neurosurgery, and psychiatry 91(1), 40-48 (2020). doi:10.1136/jnnp-2019-321073
Journal of Neurology, Neurosurgery, and Psychiatry
ISSN: 1468-330X
0022-3050
DOI: 10.1136/jnnp-2019-321073
Popis: ObjectiveThere is still an urgent need for supportive minimally invasive and cost-effective biomarkers for early diagnosis of Alzheimer’s disease (AD). Previous work in our lab has identified Kallikrein-8 (KLK8) as a potential candidate since it shows an excessive increase in human brain in preclinical disease stages. The aim of this study was to evaluate the diagnostic performance of cerebrospinal fluid (CSF) and blood KLK8 for AD and mild cognitive impairment (MCI) due to AD.MethodsIn this multi-centre trans-sectional study, clinical and laboratory data as well as CSF and/or blood serum samples of 237 participants, including 98 patients with mild AD, 21 with MCI due to AD and 118 controls were collected. CSF and/or serum KLK8 levels were analysed by ELISA. The diagnostic accuracy of KLK8 in CSF and blood was determined using receiver operating characteristic (ROC) analyses and compared with that of CSF core biomarkers Aβ42, P-tau and T-tau.ResultsThe diagnostic accuracy of CSF KLK8 was as good as that of core CSF biomarkers for AD (area under the curve (AUC)=0.89) and in case of MCI (AUC=0.97) even superior to CSF Aβ42. Blood KLK8 was a similarly strong discriminator for MCI (AUC=0.94) but slightly weaker for AD (AUC=0.83).ConclusionsThis is the first study to demonstrate the potential clinical utility of blood and CSF KLK8 as a biomarker for incipient AD. Future prospective validation studies are warranted.
Databáze: OpenAIRE
Externí odkaz: